Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 1

Submit an article Journal homepage

149

Views

CrossRef citations to date

Altmetric

Review

New generation pharmacotherapy in elderly multiple myeloma patients

Selmin A Ataergin Gulhane (GATA) Faculty of Medicine Department of Medical Oncology and Bone Marrow Transplantation Unit, 06018, Etlik, Ankara, Turkey

, MD,

Tamila Kindwall-Keller University Hospitals Case Medical Center, Department of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA +1 216 844 3629; +1 216 844 5979; [email protected]

, DO,

Nathan A Berger University Hospitals Case Medical Center, Department of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA +1 216 844 3629; +1 216 844 5979; [email protected]

, MD &

Hillard M Lazarus University Hospitals Case Medical Center, Department of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA +1 216 844 3629; +1 216 844 5979; [email protected]

, MD FACP

Pages 81-98 | Published online: 16 Dec 2008

Cite this article
https://doi.org/10.1517/14656560802611808

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Gautier M, Cohen HJ. Multiple myeloma in the elderly. J Am Geriatr Soc 1994;42:653-64
PubMed Web of Science ®Google Scholar
Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-9
PubMed Web of Science ®Google Scholar
Richardson PG, Mitsiades C, Schlossman R, et al. New drugs for myeloma. Oncologist 2007;12:664-89
PubMed Web of Science ®Google Scholar
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
PubMed Web of Science ®Google Scholar
Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-6
PubMed Web of Science ®Google Scholar
Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer- treatment trials. N Engl J Med 1999;341:2061-7
PubMed Web of Science ®Google Scholar
Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994;74:2208-14
PubMed Web of Science ®Google Scholar
Turesson I, Abildgaard N, Ahlgren T, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 1999;106:1005-12
PubMed Web of Science ®Google Scholar
Klepin HD, Hurd DD. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions? Bone Marrow Transplant 2006;38:585-92
PubMed Web of Science ®Google Scholar
Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000;35:181-200
PubMed Web of Science ®Google Scholar
Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14-34
PubMed Web of Science ®Google Scholar
Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993;20:43-9
PubMed Web of Science ®Google Scholar
Broughton DL, Taylor R. Review: deterioration of glucose tolerance with age: the role of insulin resistance. Age Ageing 1991;20:221-5
PubMed Web of Science ®Google Scholar
Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: Harris MI, editor. Diabetes in America, 2nd edition. NIH Publication No. 95-1468;1995. p. 47-67
Google Scholar
Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity and body mass index. J Bone Miner Res 2000;15:322-31
PubMed Web of Science ®Google Scholar
Berger C, Langsetmo L, Joseph L, et al. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ 2008;178:1660-8
PubMed Web of Science ®Google Scholar
Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64
PubMed Web of Science ®Google Scholar
Van Zant G, Liang Y. The role of stem cells in aging. Exp Hematol 2003;31:659-72
PubMed Web of Science ®Google Scholar
Yung RL. Changes in immune function with age. Rheum Dis Clin North Am 2000;26:455-73
PubMedGoogle Scholar
Silvestris F, Tucci M, Quatraro C, et al. Recent advances in understanding the pathogenesis of anemia in multiple myeloma. Int J Hematol 2003;78:121-5
PubMedGoogle Scholar
Hitzler JK, Martinez-Valdez H, Bergsagel DB, et al. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 1991;78:1996-2004
PubMed Web of Science ®Google Scholar
Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am 2000;14:45-61
PubMed Web of Science ®Google Scholar
Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18
PubMed Web of Science ®Google Scholar
Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54
PubMed Web of Science ®Google Scholar
Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20
PubMed Web of Science ®Google Scholar
Hungria VT, Maiolino A, Martinez G, et al. International Myeloma Working Group Latin America. Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica 2008;93:791-2
PubMedGoogle Scholar
Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007;109:3489-95
PubMed Web of Science ®Google Scholar
Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610-7
PubMed Web of Science ®Google Scholar
Alexanian R, Haut A, Khan A, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-5
PubMed Web of Science ®Google Scholar
Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292-8
PubMed Web of Science ®Google Scholar
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
PubMed Web of Science ®Google Scholar
Haas PS, Denz U, Ihorst G, et al. Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. Eur J Haematol 2008;80:303-9
PubMed Web of Science ®Google Scholar
Denz U, Haas PS, Wäsch R, et al. State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer 2006;42:1591-600
PubMed Web of Science ®Google Scholar
Palumbo A, Bringhen S, Caravita T, et al. Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31
PubMed Web of Science ®Google Scholar
Attal M, Harousseau JL, Leyvraz S, et al; Inter-Groupe Francophone du Myélome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-94
PubMed Web of Science ®Google Scholar
Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18
PubMed Web of Science ®Google Scholar
Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 2005;104:1428-33
PubMed Web of Science ®Google Scholar
Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood 2008;112:3107-14
PubMed Web of Science ®Google Scholar
Hulin C, Facon T, Rodon P, et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥ 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01 [abstract #75]. Blood 2007;110:31a
Google Scholar
Waage A, Gimsing P, Juliusson G, et al. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomized phase 3 trial [abstract #78]. Blood 2007;110:32a
Web of Science ®Google Scholar
Carlson K, Hjorth M, Knudsen LM. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure – a retrospective analysis and recommendations for dose adjustment. Br J Haematol 2005;128:631-5
PubMed Web of Science ®Google Scholar
Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004;89:826-31
PubMed Web of Science ®Google Scholar
Hussein MA, McCoy J, Jakubowiak A, et al. SWOG 0204; Phase 2 trial of thalidomide (T) + dexamethasone (D) induction followed by tandem autotransplant (TAT) and prednisone (P) + T maintenace for multiple myeloma (MM)[abstract #1169]. Blood 2005;106:341a-42a
Google Scholar
Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23
PubMed Web of Science ®Google Scholar
Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-9
PubMed Web of Science ®Google Scholar
Dingli D, Rajkumar SV, Nowakowski GS, et al. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a Phase II trial. Haematologica 2005;90:1650-4
PubMed Web of Science ®Google Scholar
Ludwig H, Drach J, Tóthová E, et al. Thalidomide-dexamethasone versus melphalan-prednisone as first line treatment in elderly patients with multiple myeloma. An interim analysis [abstract #782]. Blood 2005;106:231a
Google Scholar
Rajkumar SV, Blood E, Vesole D, et al. Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-6
PubMed Web of Science ®Google Scholar
Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-7
PubMed Web of Science ®Google Scholar
Palumbo A, Rajkumar SV, Dimopoulos MA, et al. International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23
PubMed Web of Science ®Google Scholar
Richardson PG, Mitsiades C, Hideshima T, et al. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 2006;6:1165-73
PubMed Web of Science ®Google Scholar
Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3
PubMed Web of Science ®Google Scholar
Rajkumar SV, Jacobus S, Callender N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group [abstract #LBA8025]. J Clin Oncol 2007;25:447s
PubMedGoogle Scholar
Rajkumar SV, Jacobus S, Callander N, et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi [abstract #8504]. J Clin Oncol 2008;26:455s
PubMedGoogle Scholar
Palumbo A, Falco P, Corradini P, et al. GIMEMA – Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA – Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-65
PubMed Web of Science ®Google Scholar
Batts ED, Sanchorawala V, Hegerfeldt Y, et al. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 2008;29:1-8
Google Scholar
Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007;47:1466-75
PubMed Web of Science ®Google Scholar
Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6
PubMed Web of Science ®Google Scholar
Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4
PubMed Web of Science ®Google Scholar
Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37
PubMed Web of Science ®Google Scholar
Richardson PG, Mitsiades C, Schlossman R, et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008;8:1053-72
PubMed Web of Science ®Google Scholar
Moreau P, Hulin C, Facon T. Frontline treatment of multiple myeloma in elderly patients. Blood Rev 2008;22:303-09
PubMedGoogle Scholar
Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17
PubMed Web of Science ®Google Scholar
Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008;49:890-5
PubMed Web of Science ®Google Scholar
Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007;137:429-35
PubMed Web of Science ®Google Scholar
Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60
PubMed Web of Science ®Google Scholar
Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-72
PubMed Web of Science ®Google Scholar
Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93:560-5
PubMed Web of Science ®Google Scholar
San Miguel JF, Schlag R, Khuageva N, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17
PubMed Web of Science ®Google Scholar
Richardson PG, Lonial S, Jakubowiak A, et al. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): a Phase I/II study [abstract #8521]. J Clin Oncol 2008;26:459s
Google Scholar
San-Miguel J, Harousseau J, Joshua D, et al. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008;26:2761-6
PubMed Web of Science ®Google Scholar
Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996;335:91-7
PubMed Web of Science ®Google Scholar
Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65
PubMed Web of Science ®Google Scholar
Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11
PubMed Web of Science ®Google Scholar
Child JA, Morgan GJ, Davies FE, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83
PubMed Web of Science ®Google Scholar
Tribalto M, Amadori S, Cudillo L, et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica 2000;85:52-8
PubMed Web of Science ®Google Scholar
Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-6
PubMed Web of Science ®Google Scholar
Fermand JP, Katsahian S, Divine M, et al. Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-33
PubMed Web of Science ®Google Scholar
Abdelkefi A, Ladeb S, Torjman L, et al. Tunisian Multiple Myeloma Study Group. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008;111:1805-10
PubMed Web of Science ®Google Scholar
Inouye SK, Peduzzi PN, Robison JT, et al. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998;279:1187-93
PubMed Web of Science ®Google Scholar
Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-7
PubMed Web of Science ®Google Scholar
Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:600-7
PubMed Web of Science ®Google Scholar
Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248-53
PubMed Web of Science ®Google Scholar
Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000;25:533-9
PubMed Web of Science ®Google Scholar
Jantunen E, Kuittinen T, Penttilä K, et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> or = 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006;37:917-22
PubMed Web of Science ®Google Scholar
Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-7
PubMed Web of Science ®Google Scholar
Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51-4
PubMed Web of Science ®Google Scholar
Dumontet C, Ketterer N, Espinouse D, et al. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplant 1998;21:1037-41
PubMed Web of Science ®Google Scholar
Lenhoff S, Hjorth M, Westin J, et al. Nordic Myeloma Study Group. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006;133:389-96
PubMed Web of Science ®Google Scholar
Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008;83:614-7
PubMed Web of Science ®Google Scholar
Reece DE, Bredeson C, Pérez WS, et al. Autologous stem cell transplantation in multiple myeloma patients < 60 vs >/= 60 years of age. Bone Marrow Transplant 2003;32:1135-43
PubMed Web of Science ®Google Scholar
Feyler S, Rawstron A, Jackson G, et al. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol 2007;139:429-39
PubMed Web of Science ®Google Scholar
Kees M, Dimou G, Sillaber C, et al. Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2003;44:1943-6
PubMed Web of Science ®Google Scholar
Dimopoulos MA, Pouli A, Zervas K, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003;14:1039-44
PubMed Web of Science ®Google Scholar
Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 2006;106:848-58
PubMed Web of Science ®Google Scholar
Zervas K, Mihou D, Katodritou E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 2007;18:1369-75
PubMed Web of Science ®Google Scholar
Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-9
PubMed Web of Science ®Google Scholar
Berenson JR, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, Phase II, single-arm study. Br J Haematol 2006;135:174-83
PubMed Web of Science ®Google Scholar
Badros AZ, Goloubeva O, Rapoport AP, et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 2005;23:4089-99
PubMed Web of Science ®Google Scholar
Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006;108:2159-64
PubMed Web of Science ®Google Scholar
Palumbo A, Avonto I, Patriarca F, et al. Bortezomib, pegylated-lyposomal-doxorubicin and dexamethasone followed by melphalan 100 mg/m2 in elderly newly diagnosed patients: an interim analysis [abstract #448]. Blood 2007;110:138a
Web of Science ®Google Scholar
Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-34
PubMed Web of Science ®Google Scholar
Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005;103:1195-200
PubMed Web of Science ®Google Scholar
Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a Phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316-9
PubMed Web of Science ®Google Scholar
Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64
PubMed Web of Science ®Google Scholar
Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32
PubMed Web of Science ®Google Scholar
Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003;21:768-71
Web of Science ®Google Scholar
Murakami H, Handa H, Abe M, et al. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol 2007;79:234-9
PubMed Web of Science ®Google Scholar
Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4
PubMed Web of Science ®Google Scholar
Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:4777-83
PubMed Web of Science ®Google Scholar
Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005;44:551-70
PubMed Web of Science ®Google Scholar
Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007;86:1022-33
PubMed Web of Science ®Google Scholar
Chapurlat RD. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Treat Endocrinol 2005;4:115-25
PubMedGoogle Scholar
Tralongo P, Repetto L, Di Mari A, et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 2004;67:112-6
PubMedGoogle Scholar
Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93
PubMed Web of Science ®Google Scholar
Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52
PubMed Web of Science ®Google Scholar
Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323-41
PubMed Web of Science ®Google Scholar
Orlowski RZ. Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Hematology Am Soc Hematol Educ Program 2006;338-47
PubMedGoogle Scholar
Fonseca R. Strategies for risk-adapted therapy in myeloma. Hematology Am Soc Hematol Educ Program 2007;2007:304-10
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

New generation pharmacotherapy in elderly multiple myeloma patients

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

New generation pharmacotherapy in elderly multiple myeloma patients

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date